| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer
|
Cao, Lu
|
|
2019
|
84 |
3 |
p. 609-620
|
artikel
|
| 2 |
A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer
|
Goel, Sanjay
|
|
2019
|
84 |
3 |
p. 567-578
|
artikel
|
| 3 |
Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients
|
Lau, Yvonne Y.
|
|
2019
|
84 |
3 |
p. 501-511
|
artikel
|
| 4 |
Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review
|
Madsen, Marie Lindhard
|
|
2019
|
84 |
3 |
p. 471-485
|
artikel
|
| 5 |
Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors
|
Valade, Elodie
|
|
2019
|
84 |
3 |
p. 621-633
|
artikel
|
| 6 |
BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha
|
Tas, Faruk
|
|
2019
|
84 |
3 |
p. 521-526
|
artikel
|
| 7 |
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
|
Chen, Xiaoying
|
|
2019
|
84 |
3 |
p. 667
|
artikel
|
| 8 |
Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
|
Eijk, Maarten van
|
|
2019
|
84 |
3 |
p. 487-499
|
artikel
|
| 9 |
Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study
|
Shiota, Masaki
|
|
2019
|
84 |
3 |
p. 561-566
|
artikel
|
| 10 |
Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment
|
Yigit, Oznur
|
|
2019
|
84 |
3 |
p. 513-520
|
artikel
|
| 11 |
Genistein combined with FOLFOX or FOLFOX–Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study
|
Pintova, Sofya
|
|
2019
|
84 |
3 |
p. 591-598
|
artikel
|
| 12 |
Identification of dinactin, a macrolide antibiotic, as a natural product-based small molecule targeting Wnt/β-catenin signaling pathway in cancer cells
|
Hussain, Aehtesham
|
|
2019
|
84 |
3 |
p. 551-559
|
artikel
|
| 13 |
Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients
|
Jin, Xuan
|
|
2019
|
84 |
3 |
p. 599-607
|
artikel
|
| 14 |
Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study
|
Kotake, Mie
|
|
2019
|
84 |
3 |
p. 655-660
|
artikel
|
| 15 |
In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models
|
Weng, Qi
|
|
2019
|
84 |
3 |
p. 527-537
|
artikel
|
| 16 |
Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response
|
Xu, Xing
|
|
2019
|
84 |
3 |
p. 635-646
|
artikel
|
| 17 |
Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
|
Kirschbrown, Whitney P.
|
|
2019
|
84 |
3 |
p. 539-550
|
artikel
|
| 18 |
Rituximab dosing in hematological malignancies: an old question, revisited
|
Morcos, Peter N.
|
|
2019
|
84 |
3 |
p. 661-666
|
artikel
|
| 19 |
Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors
|
Philpot, Rex M.
|
|
2019
|
84 |
3 |
p. 579-589
|
artikel
|
| 20 |
The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients
|
Ishimoto, Utako
|
|
2019
|
84 |
3 |
p. 647-654
|
artikel
|
| 21 |
The role of thioredoxin system in cancer: strategy for cancer therapy
|
Jia, Jin-Jing
|
|
2019
|
84 |
3 |
p. 453-470
|
artikel
|
Tijdschrift beschrijving